Financial Performance - The estimated net profit attributable to shareholders for 2024 is projected to be between ¥45 million and ¥65 million, representing a decline of 76.10% compared to the previous year's profit of ¥271.97 million [4]. - The net profit after deducting non-recurring gains and losses is expected to be between ¥26.1 million and ¥39.1 million, reflecting a decrease of 89.91% to 84.89% from last year's profit of ¥258.79 million [4]. Revenue Decline - The decline in revenue is attributed to the impact of policies such as centralized procurement and the MAH system, leading to a strategic transformation and an increase in self-owned equity products [6]. Production Challenges - The company has not yet achieved significant production volume in its commercial operations, resulting in high depreciation costs due to the solidification of production lines [8]. R&D Investment Impact - Increased investment in innovative drug research and development has significantly impacted profits, contributing to the overall decline in net profit [9]. Investor Guidance - The financial data for the 2024 fiscal year will be detailed in the company's annual report, urging investors to make cautious decisions and be aware of investment risks [10].
百诚医药(301096) - 2025 Q4 - 年度业绩预告